Results 91 to 100 of about 82,478 (265)

A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1

open access: yesBiosensors & bioelectronics: X
PD1/PD-L1 checkpoint inhibitors are at the forefront of cancer immunotherapies. However, the overall response rate remains only 10–30%. Even among initial responders, drug resistance often occurs, which can lead to prolonged use of a futile therapy in ...
Yuqian Zhang   +6 more
semanticscholar   +1 more source

Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness

open access: yesAmerican Journal of Physiology - Lung cellular and Molecular Physiology, 2022
Critically ill patients manifest many of the same immune features seen in coronavirus disease 2019 (COVID-19), including both “cytokine storm” and “immune suppression.” However, direct comparisons of molecular and cellular profiles between ...
E. Morrell   +29 more
semanticscholar   +1 more source

Cobalt/Photoredox Catalyzed Desymmetrization of Oxo and Azabicycles via Asymmetric Reductive Coupling With Alkynes

open access: yesAdvanced Science, EarlyView.
A one‐step, asymmetric reductive coupling of alkynes and oxa‐ and aza‐bicyclic olefins using a cobalt/photoredox catalytic system through desymmetrization. ABSTRACT Bicyclo[2.2.1]heptane frameworks represent a privileged structural motif prevalent in numerous natural products and bioactive molecules.
Subhankar Pradhan   +5 more
wiley   +1 more source

Checkpoint Imbalance in Primary Glomerulopathies: Comparative Insights into IgA Nephropathy and Membranoproliferative Glomerulonephritis

open access: yesCells
Introduction: Primary glomerulopathies are immune-driven kidney diseases. IgA nephropathy (IgAN) and membranoproliferative glomerulonephritis (MPGN) are prevalent entities with a risk of chronic progression. Immune checkpoints, such as PD-1/PD-L1, CTLA-4/
Sebastian Mertowski   +5 more
doaj   +1 more source

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble NKG2D ligands are associated with
Jinyu Zhang   +5 more
doaj   +1 more source

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer

open access: yes, 2021
Approximately 20% of breast cancer (BC) patients suffer from distant metastasis. The incidence and prevalence rates of metastatic BC have increased annually.
Kibum Jeon   +4 more
core   +1 more source

Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration.

open access: yesInternational Immunopharmacology
Dendritic cells (DCs) orchestrate both immune activation and immune tolerance in multiple sclerosis (MS). Manipulating the phenotypes and functions of DCs to boost their tolerogenic potential is an appealing strategy for treating MS and its animal model ...
Yan Mi   +9 more
semanticscholar   +1 more source

Nanozymes for Advanced Hemoglobin‐Based Oxygen Carriers: Applications in Blood Substitution, Wound Healing, Antitumor Therapy, and Beyond

open access: yesAdvanced Science, EarlyView.
This review explores how hemoglobin‐based oxygen carriers (HBOCs) combined with nanozymes create multifunctional materials that deliver oxygen while maintaining redox homeostasis. Beyond artificial blood substitutes, these constructs enable wound healing with light‐triggered oxygen release, cancer therapy through enhanced oxygenation and reactive ...
Despoina Douka   +4 more
wiley   +1 more source

Supplemental Figure 4 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

open access: yes, 2021
Soluble PD-L1 concentrations in sera in LY3300054 monotherapy ...
Wu-Chou Su (216249)   +17 more
core   +1 more source

Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function

open access: yesAdvanced Science, EarlyView.
This review explains how Extracellular vesicles‐producing cells can be endogenously engineered to load therapeutic proteins and nucleic acids. We summarize physiological and genetic strategies that harness native sorting pathways for selective cargo loading.
Jinghui Wang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy